Skip to content
Cartherics Logo Cartherics Logo
  • Our Company
    • About Us
    • Our Vision & Mission
    • Founders
    • Board Members & Key Executives
    • Scientific Consultants
    • Partners & Collaborations
    • Our Lab
  • Technology
    • Our Technology
  • Pipeline
    • Our Pipeline
    • Scientific Publications
    • Scientific & Company Presentations
  • Careers
    • Careers at Cartherics
    • Education Opportunities
  • Latest News
  • Investors
  • Contact Us

Latest News

Home » Latest News
Latest Newscarth_admin2026-06-02T11:12:27+10:00
  • Categories: General

    Breakthrough FDA approval for first solid tumor cell therapy signals new era for cancer treatment

    Published On: August 8th, 2024

    Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating [...]

    Read More
  • Categories: General

    Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy

    Published On: July 25th, 2024

    Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics’ iPSC cell line. Cartherics, The University of [...]

    Read More
  • Categories: General Investor News The Pipeline

    Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

    Published On: June 14th, 2024

    In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work [...]

    Read More
  • Categories: General Investor News The Pipeline

    Cartherics secures Australian patent for innovative cancer cell therapy

    Published On: June 12th, 2024

    Melbourne, Australia, 12 June 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for [...]

    Read More
  • Categories: General Investor News The Pipeline

    Cartherics granted European patent for multiple development candidates

    Published On: May 23rd, 2024

    Melbourne, Australia, 23 May 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for [...]

    Read More
  • Categories: Conferences General The Pipeline

    Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer

    Published On: May 22nd, 2024

    Cartherics’ CEO, Prof. Alan Trounson AO recently presented at Private Capital 2024 held at the ASX Building in Sydney. During [...]

    Read More
  • Categories: General The Pipeline

    Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments

    Published On: May 14th, 2024

    Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics' innovative approach to using stem cells to [...]

    Read More
  • Categories: General People & Careers

    The first baby from a frozen embryo turns 40!

    Published On: May 2nd, 2024

    Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of [...]

    Read More
  • Categories: General

    Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

    Published On: April 26th, 2024

    Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum  Background The recent acquisition of ImmunoGen by [...]

    Read More
  • Categories: General The Pipeline

    Cartherics enters into Collaborative Research Agreement with TiCARos

    Published On: April 2nd, 2024

      Melbourne, Australia, 2 April 2024 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the [...]

    Read More
  • Categories: General The Pipeline

    Cartherics executes Option Agreement with The Ohio State University

    Published On: March 20th, 2024

    TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 –  Cartherics Pty Ltd (“Cartherics” or [...]

    Read More
  • Categories: Conferences General Investor News The Pipeline

    Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

    Published On: March 19th, 2024

    At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company's [...]

    Read More
  • Categories: General Philanthropy The Pipeline

    Teal Ribbon Day: Raising awareness for ovarian cancer

    Published On: February 28th, 2024

    Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed [...]

    Read More
  • Categories: Conferences General Investor News The Pipeline

    Cartherics to present and exhibit at Emergence 2024

    Published On: February 22nd, 2024

    Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at [...]

    Read More
  • Categories: General Investor News The Pipeline

    Cartherics’ CEO discusses the future of solid tumour therapy

    Published On: February 15th, 2024

    Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the [...]

    Read More
Previous345Next
  • Our Company
  • Technology
  • Pipeline
  • Latest News
  • Investors

12 Ferntree Place
Notting Hill VIC 3168
AUSTRALIA

info@cartherics.com

+61 1300 973 415

About us

Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer and endometriosis.

Sign up to our newsletter

Stay informed about our latest news and developments

* indicates required


© Copyright 2022 – 2026| Cartherics Pty Ltd

Page load link

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Cartherics
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Go to Top